247 related articles for article (PubMed ID: 32160736)
1. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest.
Sadeghi S; Esmaeili S; Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Bashash D
Turk J Haematol; 2020 Aug; 37(3):167-176. PubMed ID: 32160736
[TBL] [Abstract][Full Text] [Related]
2. Anti-leukemic effect of PI3K inhibition on chronic myeloid leukemia (CML) cells: shedding new light on the mitigating effect of c-Myc and autophagy on BKM120 cytotoxicity.
Shiri Heris R; Safaroghli-Azar A; Yousefi AM; Hamidpour M; Bashash D
Cell Biol Int; 2020 May; 44(5):1212-1223. PubMed ID: 32068318
[TBL] [Abstract][Full Text] [Related]
3. Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
Safaroghli-Azar A; Bashash D; Kazemi A; Pourbagheri-Sigaroodi A; Momeny M
Eur J Pharmacol; 2019 Jan; 842():89-98. PubMed ID: 30401630
[TBL] [Abstract][Full Text] [Related]
4. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
Allegretti M; Ricciardi MR; Licchetta R; Mirabilii S; Orecchioni S; Reggiani F; Talarico G; Foà R; Bertolini F; Amadori S; Torrisi MR; Tafuri A
Sci Rep; 2015 Dec; 5():18137. PubMed ID: 26674543
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
Bashash D; Delshad M; Riyahi N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M
Eur J Pharmacol; 2018 Dec; 841():10-18. PubMed ID: 30316766
[TBL] [Abstract][Full Text] [Related]
6. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
Pereira JK; Machado-Neto JA; Lopes MR; Morini BC; Traina F; Costa FF; Saad ST; Favaro P
Eur J Cancer; 2015 Sep; 51(14):2076-85. PubMed ID: 26238016
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
Alipour F; Riyahi N; Safaroghli-Azar A; Sari S; Zandi Z; Bashash D
Int J Biochem Cell Biol; 2019 Nov; 116():105615. PubMed ID: 31539632
[TBL] [Abstract][Full Text] [Related]
8. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
Lonetti A; Antunes IL; Chiarini F; Orsini E; Buontempo F; Ricci F; Tazzari PL; Pagliaro P; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Barata JT; Martelli AM
Leukemia; 2014 Jun; 28(6):1196-206. PubMed ID: 24310736
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of nvp-bkm120 in human osteosarcomas cells.
Bavelloni A; Focaccia E; Piazzi M; Orsini A; Ramazzotti G; Cocco L; Blalock W; Faenza I
J Cell Physiol; 2019 Jul; 234(7):10907-10917. PubMed ID: 30536897
[TBL] [Abstract][Full Text] [Related]
10. Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120.
Bashash D; Delshad M; Safaroghli-Azar A; Safa M; Momeny M; Ghaffari SH
Int J Biochem Cell Biol; 2017 Oct; 91(Pt A):1-8. PubMed ID: 28834761
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
Bashash D; Safaroghli-Azar A; Delshad M; Bayati S; Nooshinfar E; Ghaffari SH
Int J Biochem Cell Biol; 2016 Oct; 79():308-317. PubMed ID: 27599915
[TBL] [Abstract][Full Text] [Related]
12. Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function.
Blanco B; Herrero-Sánchez C; Rodríguez-Serrano C; Sánchez-Barba M; Del Cañizo MC
Int Immunopharmacol; 2015 Sep; 28(1):675-85. PubMed ID: 26256696
[TBL] [Abstract][Full Text] [Related]
13. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
Koul D; Fu J; Shen R; LaFortune TA; Wang S; Tiao N; Kim YW; Liu JL; Ramnarian D; Yuan Y; Garcia-Echevrria C; Maira SM; Yung WK
Clin Cancer Res; 2012 Jan; 18(1):184-95. PubMed ID: 22065080
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
[TBL] [Abstract][Full Text] [Related]
16. Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
Liang YC; Wu HG; Xue HJ; Liu Q; Shi LL; Liu T; Wu G
J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):845-851. PubMed ID: 24337846
[TBL] [Abstract][Full Text] [Related]
17. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
[TBL] [Abstract][Full Text] [Related]
18. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
[TBL] [Abstract][Full Text] [Related]
19. Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
Ren H; Guo H; Thakur A; Zhang S; Wang T; Liang Y; Shi P; Gao L; Liu F; Feng J; Chen T; Yang T; Shang D; Liu JJ; Xu F; Chen M
Oncotarget; 2016 Oct; 7(41):67277-67287. PubMed ID: 27572309
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.
Brachmann SM; Kleylein-Sohn J; Gaulis S; Kauffmann A; Blommers MJ; Kazic-Legueux M; Laborde L; Hattenberger M; Stauffer F; Vaxelaire J; Romanet V; Henry C; Murakami M; Guthy DA; Sterker D; Bergling S; Wilson C; Brümmendorf T; Fritsch C; Garcia-Echeverria C; Sellers WR; Hofmann F; Maira SM
Mol Cancer Ther; 2012 Aug; 11(8):1747-57. PubMed ID: 22653967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
